INTRODUCTION AND OBJECTIVES:
Hemorrhagic cystitis is a highly-morbid inflammatory bladder disease associated with nitrogen mustard alkylating agents, most notably cyclophosphamide. Acrolein, a reactive oxygen species metabolite of cyclophosphamide, has been shown to silence DNA damage repair genes via global methylation pathways. 8-oxoguanine DNA glycosylase (Ogg1) is one such silenced base excision repair enzyme that can restore DNA integrity. Subsequent inflammation from the accumulation of DNA damage results in bladder smooth muscle pyroptotic cell death. We hypothesized that reversing inflammasome-induced imprinting and gene silencing in the bladder smooth muscle could prevent hemorrhagic cystitis.
METHODS: Experiments were carried out using cultured detrusor fibroblasts, B6 wild-type mice, and Ogg1 knockout mice. Hemorrhagic cystitis was induced with either cyclophosphamide or acrolein. Mesna, the current standard of care treatment to prevent hemorrhagic cystitis; Nicotinamide, a vitamin B-3 analog shown to ameliroate bladder inflammation; and suberoylanilide hydroxamic acid, a histone deacetylase (HDAC) inhibitor with anti-inflamatory properties, were added to treatment groups. Harvested tissues and cells were subjected to bisulfite sequencing and chromatin immunoprecipitation analysis to evaluate DNA methylation patterns and epigenetic imprinting.
RESULTS: There was enhanced recruitment of Dnmt1 and Dnmt3b to the Ogg1 promoter in acrolein treated bladder fibroblasts as demonstrated by the pattern of CpG-island methylation and resultant bisulfite sequencing. Accumulation of reactive oxygen species with spontaneous pyroptotic signaling was found in Ogg1 knockout detrusor cells. Suberoylanilide hydroxamic acid restored Ogg1 expression to physiologic levels moreso than either nicotinamide or Mesna in all hemorrhagic cystitis models. Additionally, suberoylanilide hydroxamic acid restored histologically-visible cyclophosphamide-induced bladder damage to that of normal untreated control mice.
CONCLUSIONS: The pattern of epigenetic imprinting induced by inflammation suggests a novel therapeutic target for the treatment of hemorrhagic cystitis. HDAC inhibitors can reactivate Ogg1 expression by altering DNA methylation through Dnmt3B regulation. More broadly, the data suggest that re-programming epigenetic imprinting could limit the inflammatory process induced by not only cyclophosphamide but by a multitude of other toxic insults as well. Clinical unilateral ureteral obstruction (UUO) results from pathologies like ureteral calculi, malignancy, trauma, and periureteral fibrosis. UUO requires prompt surgical intervention to prevent progressive inflammation, fibrosis, and kidney function impairment. Novel therapies are needed to recover renal function and architecture after obstruction. Previous reports show the anti-inflammatory cytokine interleukin-10 (IL-10) attenuates fibrosis in a murine model. We and others have shown IL-10 regulates angiogenesis and endothelial progenitor recruitment during dermal and ischemic cardiac tissue repair. We hypothesize that IL-10 can promote angiogenesis and prevent microvascular rarefaction in a murine UUO model.
METHODS: 8 week-old C57BL/6J (WT) mice and IL-10 null male mice were injected with lenti-IL-10/lenti-GFP (1x10 10 IU) under the renal capsule. Three days after injection, UUO was performed. 14 days after UUO, UUO/sham kidneys and serum were collected for RNA, ELISA and immunohistochemical analysis of VEGF and TGFb isoforms. Primary fibroblasts were isolated from 8-10 week-old male WT mice. IL-10 (50 ng/ml or 200 ng/ml) was added to cultures. VEGF and TGFb-1 gene expressions were assessed by qPCR at 1, 2, 3 and 6h. Levels of TGFb-1 and TGFb-3 were determined at 48h by ELISA. Data presented as meanAESD, n¼3/treatment group. P value by ANOVA.
RESULTS: IL-10 treatment, in vitro, increased VEGF expression (related to physiologic angiogenesis) and altered the expression of TGFb isoforms (related to pathologic fibrosis). Lenti-Il10 treatment in mice with UUO reduced fibrotic changes between tubules (45AE7%, p<0.05) and attenuated tubular dilatation (p<0.05, n¼30/group). CD31, an endothelium marker essential to preserving tubular integrity, was normally expressed in healthy kidney parenchyma and decreased after UUO. IL-10 null mice showed a lower basal level of CD31 than WT mice. In both WT and IL-10 null mice, IL-10 treatment preserved CD31, suggesting a role in rescuing integral peritubular capillaries.
CONCLUSIONS: Ureteral obstruction can cause remodeled renal architecture and decrease in renal function. Our results in a murine UUO model show that IL-10 can effectively promote angiogenesis in vitro and prevent microvascular rarefaction in vivo. Mice treated with IL-10 show decreased fibrotic change and increased markers for tubular integrity. These results from the in vivo studies of UUO, and the in vitro studies of IL-10 0 s influence in angiogenesis and fibrosis of the kidney, may lead to novel treatments for the sequelae of urinary tract obstruction. . 197, No. 4S, Supplement, Friday, May 12, 2017 
